Prothena Corp Plc (PRTA) Implied Volatility Current

Tracking PRTA implied volatility helps you identify when options premiums on Prothena Corp Plc are historically cheap or expensive, and where the best trades are hiding. Prothena Corp Plc implied volatility reflects the market's expectation of future price movement: when PRTA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Prothena Corp Plc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For PRTA, tracking metrics like PRTA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on PRTA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where PRTA implied volatility sits today versus where it has been. Our scanner ranks Prothena Corp Plc implied volatility against its historical range, surfaces extremes in PRTA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Prothena Corp Plc IV is rich or cheap — measure it, then act on it.